We are live on
!
Find out more
LSV Asset Management Portfolio holdings
AUM
$46.4B
1-Year Est. Return
27.74%
This Fund
S&P 500
This Quarter
Est. Return
-5.56%
1 Year Est. Return
+27.74%
3 Year Est. Return
+73.33%
5 Year Est. Return
+93.31%
10 Year Est. Return
+303.34%
AUM
$42.6B
AUM Growth
-$3.68B
(-8%)
Cap. Flow
-$430M
Cap. Flow
% of AUM
-1.01%
Top 10 Holdings %
Top 10 Hldgs %
14.5%
Holding
923
New
31
Increased
229
Reduced
432
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$95.7M |
| 2 |
Incyte
INCY
|
+$78.3M |
| 3 |
Wells Fargo
WFC
|
+$66.4M |
| 4 |
UGI
UGI
|
+$62.2M |
| 5 |
Winnebago Industries
WGO
|
+$36.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$87.7M |
| 2 |
L3Harris
LHX
|
+$83.8M |
| 3 |
Allstate
ALL
|
+$76.4M |
| 4 |
Murphy USA
MUSA
|
+$74.1M |
| 5 |
AAWW
Atlas Air Worldwide Holdings, Inc.
AAWW
|
+$73.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 20.81% |
| 2 | Healthcare | 17.54% |
| 3 | Technology | 13.57% |
| 4 | Consumer Discretionary | 11.77% |
| 5 | Industrials | 9.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
651
Thermo Fisher Scientific
TMO
$213B
| $964K | ﹤0.01% |
1,900
| – | – |
|
652
Utah Medical Products
UTMD
$225M
| $930K | ﹤0.01% |
10,901
-1,799
| -14% | -$159K |
|
653
OP Bancorp
OPBK
$232M
| $929K | ﹤0.01% |
83,500
-14,894
| -15% | -$171K |
|
654
Varex Imaging
VREX
$472M
| $929K | ﹤0.01% |
43,954
+40,787
| +1,288% | +$892K |
|
|
BRKL
655
DELISTED
Brookline Bancorp
BRKL
| $917K | ﹤0.01% |
78,700
+3,300
| +4% | +$43.7K |
|
656
Costamare
CMRE
$1.88B
| $909K | ﹤0.01% |
101,600
| – | – |
|
657
Crawford & Co Class B
CRD.B
$491M
| $877K | ﹤0.01% |
167,026
-2,600
| -2% | -$16.4K |
|
|
ADAM
658
Adamas Trust
ADAM
$815M
| $847K | ﹤0.01% |
90,524
-238,726
| -73% | -$2.71M |
|
659
Avis
CAR
$4.86B
| $846K | ﹤0.01% |
+5,700
| New | +$937K |
|
660
CRA International
CRAI
$1.16B
| $836K | ﹤0.01% |
9,418
-1,214
| -11% | -$111K |
|
661
Supernus Pharmaceuticals
SUPN
$2.59B
| $833K | ﹤0.01% |
24,600
-3,100
| -11% | -$101K |
|
662
GSK
GSK
$104B
| $831K | ﹤0.01% |
28,240
| – | – |
|
663
McDonald's
MCD
$192B
| $831K | ﹤0.01% |
3,600
| – | – |
|
664
Simmons First National
SFNC
$3.41B
| $818K | ﹤0.01% |
37,553
-79,086
| -68% | -$1.83M |
|
665
BCB Bancorp
BCBP
$173M
| $791K | ﹤0.01% |
47,000
-24,000
| -34% | -$441K |
|
|
LBC
666
DELISTED
Luther Burbank Corporation Common Stock
LBC
| $788K | ﹤0.01% |
67,800
-47,112
| -41% | -$606K |
|
|
SMMF
667
DELISTED
Summit Financial Group, Inc.
SMMF
| $776K | ﹤0.01% |
28,800
-13,385
| -32% | -$383K |
|
668
ENI
E
$80.5B
| $774K | ﹤0.01% |
36,600
| – | – |
|
669
Chemed
CHE
$7.07B
| $733K | ﹤0.01% |
1,680
| – | – |
|
670
Blue Ridge Bankshares
BRBS
$315M
| $732K | ﹤0.01% |
57,591
+29,904
| +108% | +$433K |
|
671
Parker-Hannifin
PH
$123B
| $727K | ﹤0.01% |
+3,000
| New | +$812K |
|
672
Wintrust Financial
WTFC
$10.8B
| $726K | ﹤0.01% |
8,900
| – | – |
|
673
Chemung Financial Corp
CHMG
$393M
| $724K | ﹤0.01% |
17,300
-10,053
| -37% | -$452K |
|
674
Patrick Industries
PATK
$2.74B
| $723K | ﹤0.01% |
24,750
-7,950
| -24% | -$289K |
|
675
Vanda Pharmaceuticals
VNDA
$307M
| $723K | ﹤0.01% |
73,200
-55,600
| -43% | -$587K |
|
Similar funds
LP
TI
LSV Asset Management's Q3 2022 Portfolio in Review
As of Q3 2022, LSV Asset Management held 923 positions worth $42.6B, down 8% from $46.2B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
LSV Asset Management's Q3 2022 filing shows 31 new, 229 increased, 432 reduced and 51 closed positions. Its largest new stake was WaFd: 583,608 shares worth $17.5M. The largest sale was Merck, an estimated $87.7M.
By sector, the portfolio is most concentrated in Financials at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Technology.
- LSV Asset Management's largest Q3 2022 buy was WaFd: 583,608 shares worth $17.5M.
- LSV Asset Management added most to Meta Platforms (Facebook) in Q3 2022, an estimated $95.7M increase.
- LSV Asset Management's biggest Q3 2022 reduction was Merck, cutting an estimated $87.7M.
- LSV Asset Management fully exited Crown Holdings in Q3 2022, selling an estimated $60.5M.
- LSV Asset Management's ten largest holdings make up 15% of its $42.6B portfolio in Q3 2022.
- LSV Asset Management opened 31 new positions and closed 51 in Q3 2022.
- LSV Asset Management's portfolio value fell 8% quarter-over-quarter to $42.6B.
Based on LSV Asset Management's 13F filing for Q3 2022, filed 4 Nov 2022.